Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Crism TherapeuticsAMMCF 35 Net Cash per Share is $0.03 as of Dec. 2025, which is 100% below its 10-year median of 10.00. GuruFocus rates AMMCF with a GF Score™ of 35/100. The stock has 3 warning signs investors should review. Among 784 Biotechnology companies, Crism Therapeutics ranks worse than 71.81% on this metric.
Crism Therapeutics (OTCPK:AMMCF) Net Cash per Share Explanation
Ben Graham invested in situations where the company's stock price was lower than its net-cash. He assigned some value to the company's other current asset. The value is called Net Current Asset Value (NCAV). One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.
You can find companies that are traded below their Net Current Asset Value (NCAV) with our Net-Net screener.
Crism Therapeutics Net Cash per Share Related Terms
Crism Therapeutics Net Cash per Share Historical Data
* Premium members only.
The historical data trend for Crism Therapeutics's Net Cash per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
AMMCF vs VRTX, REGN, RVMD: Net Cash per Share Comparison
For the Biotechnology subindustry, Crism Therapeutics's Price-to-Net-Cash, along with its competitors' market caps and Price-to-Net-Cash data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Crism Therapeutics Price-to-Net-Cash vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Crism Therapeutics's Price-to-Net-Cash distribution charts can be found below:
* The bar in red indicates where Crism Therapeutics's Price-to-Net-Cash falls into.
In the calculation of a company's Net Cash per Share, assets other than cash and short term investments are considered to be worth nothing. But the company has to pay its debt and other liabilities in full. This is an extremely conservative way of valuation. Most companies have negative Net Cash per Share. But sometimes a company's price may be lower than its net-cash.
Crism Therapeutics's Net Cash per Share for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Crism Therapeutics (AMMCF) has a Net Cash per Share of $0.03 as of Dec. 2025. Net cash per share equals the per-share value of cash and equivalents less total liabilities and minority interest. View historical data on Crism Therapeutics and its competitors. This is 100% below median its historical median of 10.00. Over the past decade, Crism Therapeutics' Net Cash per Share has ranged from 3.16 to 38.05. According to the industry distribution chart, Crism Therapeutics ranks #563 out of 784 companies in the Biotechnology industry, placing it in the top 71.8%.
Is Crism Therapeutics' Net Cash per Share too high?
Crism Therapeutics' current Net Cash per Share of $0.03 is 100% below median its 10-year median of 10.00. Over the past 10 years, this metric has ranged from a low of 3.16 to a high of 38.05. The Biotechnology industry median Net Cash per Share is 5.16. Crism Therapeutics' value of $0.03 is 99.4% below this industry median. Based on the distribution chart, Crism Therapeutics ranks #563 out of 784 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Crism Therapeutics has a GF Score™ of 35/100, reflecting its overall financial health beyond just this single metric.
How does Crism Therapeutics' Net Cash per Share compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Crism Therapeutics ranks #563 out of 784 companies for Net Cash per Share. This places Crism Therapeutics in the lower half of its industry. The industry median Net Cash per Share is 5.16. Crism Therapeutics' value of $0.03 is 99.4% below this benchmark. Historically, Crism Therapeutics' own Net Cash per Share has ranged from 3.16 to 38.05 over the past decade. While the company's 10-year median is 10.00 vs. the industry median of 5.16, Crism Therapeutics has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Cash per Share for a Biotechnology company?
The median Net Cash per Share among Biotechnology companies is 5.16, based on 784 companies in the industry. Companies in the top quartile (top 25%) have a Net Cash per Share significantly above this median, while those in the bottom quartile fall well below. However, Net Cash per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Crism Therapeutics's current Net Cash per Share of $0.03 is 99.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Cash per Share mean?
A high Net Cash per Share can signal that a stock is expensive relative to its fundamentals. Net cash per share equals the per-share value of cash and equivalents less total liabilities and minority interest. View historical data on Crism Therapeutics and its competitors. For the Biotechnology industry, the median Net Cash per Share is 5.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Crism Therapeutics's current Net Cash per Share is $0.03, which is 100% below median its own 10-year median of 10.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Crism Therapeutics stock overvalued right now?
Crism Therapeutics (AMMCF) has a current Net Cash per Share of $0.03. The current Net Cash per Share is $0.03, which is 100% below median its 10-year median of 10.00 and 99.4% below the Biotechnology industry median of 5.16. Crism Therapeutics' overall GF Score™ is 35/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Cash per Share calculated?
Net Cash per Share is calculated from a company's financial statements. For Crism Therapeutics (AMMCF), the current Net Cash per Share is $0.03 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Crism Therapeutics Corp has developed a drug delivery technology to improve the clinical performance of cancer treatments for solid tumours through the local delivery of chemotherapy drugs. Its product ChemoSeed which is in its clinical trial phase, can be implanted directly into the tumour or the resection margin following the removal of a tumour. The company also provides consultancy and formulation services to its clients assisting them with pharmaceutical formulation and development.
35GF Score
Get the complete analysis for AMMCF
Net Cash per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
AMMCF has been successfully added to your 
